Radioligand Therapy (RLT) Market: A ‘Game Changer’ for Cancer Treatment

The Radioligand Therapy Market is expected to reach a US$13 billion market at a growth rate of ~5% by 2030. Increasing prevalence of various types of cancer, including prostate cancer and neuroendocrine tumors, advancements in nuclear medicine in the field of radiopharmaceutical development, a rising geriatric population, increasing awareness and understanding of radiotherapy isotopes, and an increase in clinical research and trial activities for developing new product pipelines are some of the key factors driving the radioligand therapy market. To get a radioligand therapy market analysis preview report.

Radioligand therapy is a form of precision nuclear medicine for patients with advanced cancers. Radioligand therapy, also called radionuclide or radiopharmaceutical therapy, is a targeted cancer treatment that delivers radiation directly to cancer cells. Radioligand therapy can enable the precise targeting of cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, enabling significant anti-tumor efficacy while limiting the impact on healthy tissue.

Advancement in Clinical Trials for Therapeutic Radiopharmaceutical Pipelines Will Drive Market Growth

Radioligand therapies have the potential to shift the standard of care in oncology. Clinical trials provide critical data on the efficacy and safety of therapeutic radiopharmaceuticals. The potential outcome helps researchers to treat various cancer types and diseases and attract investment from pharmaceutical companies. Therefore, advancements in clinical trials for therapeutic radiopharmaceutical pipelines have the potential to significantly drive market growth in the field. For instance,

• In December 2023, Lantheus Holdings, Inc. and POINT Biopharma Global Inc. announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor (ARPI).

Emerging Applications of Radioligand Therapy in Neuroendocrine Neoplasms, Prostate Cancer, and Non-cancerous Conditions Fuel its Demand in the Market

The newest applications of radioligands focus on NETs and bone metastases in mCRPC, with research ongoing in many other cancer and non-cancer conditions as well. Radioligand therapy delivers radiation directly to select types of cells, and it is gradually emerging as an essential pillar in?cancer care. Some of the emerging applications of radioligand therapy include:

1. Neuroendocrine Neoplasms (NETs): Radioligand therapy has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs), which arise from neuroendocrine cells and can occur in various organs. Radioligand therapy improves progression-free survival and overall disease?control and reduces tumor size.
2. Prostate Cancer: PSMA radioligand therapy utilizing urea-based agents with a- and β-particle emitting radionuclides example Lutetium-177, Actinium-225, Thorium-227, Terbium-161, Lead 212, etc. has been identified as a promising approach for hormone-sensitive as well as castrate-resistant prostate cancer patients.
3. Non-cancerous Conditions: The primary focus of radioligand therapy is on cancer treatment, researchers are also exploring how the approach could be utilized in other non-cancerous conditions. For example: inflammatory conditions and arthritis.

Key Constraints/Challenges

The initial and ongoing costs associated with the treatment can be significant. There are very few healthcare professionals trained in radioligand therapy which restricts the use of the approach to a small number of specialist centers. The regulatory frameworks for radioligands must also evolve to suit this emerging treatment modality. Radioligand therapy is a targeted form of cancer treatment and is only viable for a few days after it’s manufactured therefore other policy advances are needed in terms of the supply of radioisotopes and nuclear waste.

North America Accounts for the Largest Share of the Global Market

North America has emerged as the predominant global market for radioligand therapy. The region experiences substantial market growth, driven by stringent regulations governing the healthcare and pharmaceutical sectors. Increasing investments from public and private funding and clinical progression for many radioligand therapy products, and a rise in the patient base suffering from cancer in the U.S. contribute significantly to the market growth.

Competitive Landscape

The top market players in the radioligand therapy market include 诺华 Orano Med Telix Pharmaceuticals Limited 礼来 and Molecular Partners

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting organic and inorganic growth strategies such as collaborations, and acquisitions to garner market share. For instance,

• In November 2023, Orano Med, a pioneer in targeted alpha therapy, and?48Hour Discovery, a novel peptide discovery platform company, announced their strategic collaboration to advance cancer treatment through radioligand discovery and development.
• In October 2023, Eli?Lilly and?POINT Biopharma Global, Inc. announced a definitive agreement for?Lilly?to acquire POINT, a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for cancer treatment.